ENTX News

Entera Bio, which is developing oral formulations of treatments for a thyroid condition and osteoporosis, raised $11.2 million by offering 1.4 million units at $8, the low end of the range of $8 to $10. Existing shareholders bought $3.4 million of the IPO (30%)....read more

Entera Bio, which is developing oral formulations of treatments for a thyroid condition and osteoporosis, reported financial results for the twelve months ended December 31, 2017, in an amendment filed with the SEC on Thursday. It originally set terms for a...read more

Entera Bio, which is developing oral formulations of treatments for a thyroid condition and osteoporosis, postponed its IPO on Monday. It had filed to raise $55 million by offering 5.0 million shares at a price range of $10 to $12, for a proposed post-IPO...read more

Ten deals are expected to price next week, raising a combined $3.1 billion in proceeds, as this month gears up to be the busiest January in over eight years in terms of proceeds raised ($3.1 billion raised to date). The week will be headlined by the "Paypal...read more